Plasma concentrations of carminomycin and carminomycinol in man, measured by high pressure liquid chromatography

J. Lankelma; P. G M Penders; J. G. McVie; A. Leyva; W. W. Ten Bokkel-Huinink; M. M. De Planque; H. M. Pinedo

doi:10.1016/0277-5379(82)90007-4

Plasma concentrations of carminomycin and carminomycinol in man, measured by high pressure liquid chromatography

J. Lankelma, P. G M Penders, J. G. McVie, A. Leyva, W. W. Ten Bokkel-Huinink, M. M. De Planque, H. M. Pinedo

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

In 9 patients with advanced malignant disease who received carminomycin (CMM) in an i.v. bolus injection (dose 18 mg/m²), curves of plasma concentrations of CMM and carminomycinol (CMMOH), a metabolite, versus time were constructed. For determination of plasma concentrations, high pressure liquid chromatography was used. For CMM and CMMOH the median areas under the curves (AUC's) were 31 (range 4-57) × 10^-8 mol/l/hr (measured over 24 hr) and 100 (range 30-158) × 10^-8 mol/l/hr (measured over 48 hr) respectively. From the data an accumulation of CMMOH in patients receiving treatments separated by brief intervals can be predicted (half-life time of plasma disappearance for CMMOH was 2 days). Clinical toxicity was lowest in those 3 patients showing the lowest AUC for both CMM and CMMOH.

Original language	English (US)
Pages (from-to)	363-367
Number of pages	5
Journal	European Journal of Cancer and Clinical Oncology
Volume	18
Issue number	4
DOIs	https://doi.org/10.1016/0277-5379(82)90007-4
State	Published - 1982
Externally published	Yes

ASJC Scopus subject areas

Oncology

Access to Document

10.1016/0277-5379(82)90007-4

Cite this

@article{330f4de490c543a285168e3a808fa421,

title = "Plasma concentrations of carminomycin and carminomycinol in man, measured by high pressure liquid chromatography",

abstract = "In 9 patients with advanced malignant disease who received carminomycin (CMM) in an i.v. bolus injection (dose 18 mg/m2), curves of plasma concentrations of CMM and carminomycinol (CMMOH), a metabolite, versus time were constructed. For determination of plasma concentrations, high pressure liquid chromatography was used. For CMM and CMMOH the median areas under the curves (AUC's) were 31 (range 4-57) × 10-8 mol/l/hr (measured over 24 hr) and 100 (range 30-158) × 10-8 mol/l/hr (measured over 48 hr) respectively. From the data an accumulation of CMMOH in patients receiving treatments separated by brief intervals can be predicted (half-life time of plasma disappearance for CMMOH was 2 days). Clinical toxicity was lowest in those 3 patients showing the lowest AUC for both CMM and CMMOH.",

author = "J. Lankelma and Penders, {P. G M} and McVie, {J. G.} and A. Leyva and {Ten Bokkel-Huinink}, {W. W.} and {De Planque}, {M. M.} and Pinedo, {H. M.}",

year = "1982",

doi = "10.1016/0277-5379(82)90007-4",

language = "English (US)",

volume = "18",

pages = "363--367",

journal = "European Journal of Cancer and Clinical Oncology",

issn = "0277-5379",

publisher = "Pergamon Press",

number = "4",

}

TY - JOUR

T1 - Plasma concentrations of carminomycin and carminomycinol in man, measured by high pressure liquid chromatography

AU - Lankelma, J.

AU - Penders, P. G M

AU - McVie, J. G.

AU - Leyva, A.

AU - Ten Bokkel-Huinink, W. W.

AU - De Planque, M. M.

AU - Pinedo, H. M.

PY - 1982

Y1 - 1982

N2 - In 9 patients with advanced malignant disease who received carminomycin (CMM) in an i.v. bolus injection (dose 18 mg/m2), curves of plasma concentrations of CMM and carminomycinol (CMMOH), a metabolite, versus time were constructed. For determination of plasma concentrations, high pressure liquid chromatography was used. For CMM and CMMOH the median areas under the curves (AUC's) were 31 (range 4-57) × 10-8 mol/l/hr (measured over 24 hr) and 100 (range 30-158) × 10-8 mol/l/hr (measured over 48 hr) respectively. From the data an accumulation of CMMOH in patients receiving treatments separated by brief intervals can be predicted (half-life time of plasma disappearance for CMMOH was 2 days). Clinical toxicity was lowest in those 3 patients showing the lowest AUC for both CMM and CMMOH.

AB - In 9 patients with advanced malignant disease who received carminomycin (CMM) in an i.v. bolus injection (dose 18 mg/m2), curves of plasma concentrations of CMM and carminomycinol (CMMOH), a metabolite, versus time were constructed. For determination of plasma concentrations, high pressure liquid chromatography was used. For CMM and CMMOH the median areas under the curves (AUC's) were 31 (range 4-57) × 10-8 mol/l/hr (measured over 24 hr) and 100 (range 30-158) × 10-8 mol/l/hr (measured over 48 hr) respectively. From the data an accumulation of CMMOH in patients receiving treatments separated by brief intervals can be predicted (half-life time of plasma disappearance for CMMOH was 2 days). Clinical toxicity was lowest in those 3 patients showing the lowest AUC for both CMM and CMMOH.

UR - http://www.scopus.com/inward/record.url?scp=0019992762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019992762&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(82)90007-4

DO - 10.1016/0277-5379(82)90007-4

M3 - Article

C2 - 6889513

AN - SCOPUS:0019992762

SN - 0277-5379

VL - 18

SP - 363

EP - 367

JO - European Journal of Cancer and Clinical Oncology

JF - European Journal of Cancer and Clinical Oncology

IS - 4

ER -

Plasma concentrations of carminomycin and carminomycinol in man, measured by high pressure liquid chromatography

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this